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Abstract
Background: Incidence of  endometrial cancer in India is increasing due to lifestyle changes and obesity. As 5 year survival 
rate of  cancer confined to uterus is good, there is need for serum tumor marker for early diagnosis. This study was designed 
to identify a tumor marker which differentiate endometrial carcinoma and abnormal uterine bleeding (AUB) because common 
presentation of  endometrial carcinoma is AUB. 
Objectives: To estimate and compare serum prolactin, Cancer Antigen 125 (CA-125), Cancer Antigen 15-3 (CA15-3), and Car-
cino embryonic antigen (CEA) levels in patients with endometrial cancer and abnormal uterine bleeding; To evaluate the role of  
these markers in diagnosing endometrial cancer. 
Methodology: Thirty eight patients with endometrial cancer and 40 patients with AUB were recruited in this study. Serum pro-
lactin, CA 125, CEA, and CA 15-3 levels were estimated in both groups. 
Results: The levels of  CA 15-3, CA 125, CEA, and prolactin were increased in endometrial carcinoma patients, on comparison 
with AUB patients. CA 125 alone was found to be a better marker to detect endometrial cancer with 52.63% sensitivity, 80.00% 
specificity. 
Conclusion: As individual tumor marker, serum CA 125 has the ability to detect endometrial cancer in patients with abnormal 
uterine bleeding.
Keywords: CA-125 antigen, CA 15-3, carcino embryonic antigen, endometrial carcinoma, prolactin, tumor marker, abnormal 
uterine bleeding.
DOI: https://dx.doi.org/10.4314/ahs.v18i4.17
Cite as: Nithin KU,  Sridhar MG, Srilatha K, Habebullah S. CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine 
bleeding. Afri Health Sci. 2018;18(4): 972-978. https://dx.doi.org/10.4314/ahs.v18i4.17
Corresponding author:
Nithin Kumar U, 
Department of  Biochemistry, 
Sri Ramachandra Institute of  Higher 
Education and Research, 




Endometrial cancer is a common gynecological malig-
nancy in women and its prevalence in India is increasing 
in last 5 years. According to GLOBOCAN 2012 statistics, 
approximately 12,300 new cases are diagnosed yearly, of  
which about 4700 women die from the disease each year 
in India1. Recently published data showed that the inci-
dence of  Endometrial cancer 4.3 per 100000 in India2. 
The overall 5-year survival rate is 86% when all stages 
combined and  for  the  disease  confined  to  the  uter-
us  is  96%3,4.  Most common presentation of  endome-
trial cancer is abnormal uterine bleeding. Among them, 
around 75% of  the women were diagnosed to have early 
stage of  endometrial cancer5. AUB being most common 
presentation in many gynecological diseases and there is a 
need for markers there is a need for markers to diagnose 
endometrial carcinoma, in patients with similar symp-
toms such as AUB. 
If  endometrial cancer is detected in early stages, treat-
ment can reduce overall mortality. Endometrial cancer 
is diagnosed either by histo-pathological examination of  
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endometrial biopsy specimen or by endometrial cytolog-
ical examination of  endometrial brush. These methods 
are invasive and, less sensitive in diagnosing endometrial 
cancer and chances of  false negative rates are high6.  This 
warrants the use of  non-invasive serum markers to detect 
endometrial cancer.
Earlier studies have estimated serum concentrations of  
Cancer Antigen -125 (CA 125) and Cancer Antigen 15-3
(CA 15 – 3) in endometrial cancer. These studies have 
demonstrated an association between preoperative se-
rum CA 125 and CA 15–3 levels with tumor stage and 
showed that these markers can be used to predict of  extra 
uterine spread of  cancer and can be used to monitor the 
response of  chemotherapy as well7,8.   Elevated CA 15-3 
indicate poor prognosis in these patients9. A study done
by Neunteufel W et al. has found 58% positivity for Car-
cino Embryonic Antigen (CEA) in immunohistochem-
istry studies done in 40 endometrial cancer cases CEA 
in immunohistochemistry studies done in 40 endometrial 
cancer cases10.
A study by Yurkovetsky Z et al. has demonstrated elevated 
prolactin levels in endometrial carcinoma and proposed 
that prolactin has got high diagnostic power in detecting 
early cancer11. Kanat-Pektas M et al. suggested that CA-
125 and prolactin are non-specific for endometrial cancer. 
As Prolactin is subjected to physiological variation, mea-
suring this hormone will have limited use in diagnosing 
endometrial cancers at initial stage. Hence, it is difficult 
to use either Prolactin or CA-125 as a single marker to 
screen endometrial cancer.  The same study also showed 
that these two markers should be included together as a 
part of  biochemical screening panel in future12.
The objective of  this study includes comparison of  tu-
mour markers in two different conditions have same 
presentation. So the patients with AUB were included as 
comparison group. The tumour markers level were com-
pared between these two groups to find out whether any 
of  the included tumour markers can be able to differ-
entiate endometrial carcinoma and AUB though there is 
common clinical presentation.
The present study is undertaken to estimate and compare 
the concentrations of  serum prolactin, CA 125, CA 15-
3, and CEA in patients with endometrial cancer and ab-
normal uterine bleeding and also to evaluate whether the 
above parameters can be used to diagnose endometrial 
cancer. 
Methodology
This study was conducted in Department of  Biochemis-
try along with Department of  Obstetrics and Gynaecolo-
gy, JIPMER, Puducherry, India. The study was approved 
by JIPMER institute ethics sub-committee- human stud-
ies, and was funded by Intramural grant from JIPMER.
Selection of  study participants
The study subjects were enrolled in the study based on in-
clusion and exclusion criteria. All perimenopausal women 
with endometrial carcinoma diagnosed by histopathologi-
cal examination were taken into group 1.  Similarly weight 
matched peri-menopausal women with abnormal uterine 
bleeding other than endometrial carcinomas were con-
sidered into group 2. All endometrial cancer patients on 
treatment and those who were taking hormone replace-
ment therapy were excluded from the study. Patients with 
abdominal tuberculosis were also excluded as elevated 
CA 125 levels are associated with this condition13.
All patients attending Gynaecology Department, JIP-
MER Hospital with symptoms of  peri-menopausal 
bleeding during reference period of  January 2011 to April 
2012 were recruited into study groups as per inclusion 
and exclusion criteria after obtaining a written informed 
consent. Thirty eight patients with endometrial carci-
noma were included in Group 1, whereas forty weight 
matched patients with abnormal uterine bleeding other 
than endometrial cancers were considered into group 2.
Data collection and Biochemical analyses
The details of  age, height and weight of  all participants 
were recorded and Body Mass Index (BMI) is calculated 
Body Mass Index BMI is calculated. The height was mea-
sured in centimeters using measuring tape and weight was 
measured in kilogram using Equinox weighing machine 
(New Delhi, India).
Five ml of  venous blood sample was collected from all 
study subjects. Serum was separated after centrifugation 
and stored at -80°C for assays of  various parameters as 
per protocol.
BMI was calculated by using Quetelet’s index, [weight /
height2] The BMI was expressed as kg/m2. Serum con-
centrations of  CA125, CEA and Prolactin were measured 
by a two-site sandwich immunoassay using direct chemi-
luminometric technology (ADVIA Centaur® CP Immu-
noassay System, Siemens, Switzerland). Whereas CA 15-3 
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was assayed using Enzyme Linked Immuno Sorbent As-
say (ELISA) kit Syntron Bioresearch, California17.  The 
reference ranges for serum CA-125, Prolactin, and CEA 
are less than 35 U/mL, 1.9–25 ng/mL and   0 - 3µg/L 
respectively.  The reference range for CA 15-3 is <33 U/
mL.
Statistical analyses
The normality of  the continuous data was checked by 
Kolmogorov-Smirnov test. Data were reported as mean 
and standard deviation for normally distributed data and 
median with interquartile range was used for non-Gauss-
ian data. The levels of  tumor makers of  two groups were 
compared either using independent t test or Mann Whit-
ney U test according to their distribution. The possible 
relationship among the values of  the tumor markers was 
assessed by correlation analysis. Sensitivity, specificity, 
positive predictive value and negative predictive value 
were calculated. Receiver operating Characteristics ROC 
curve was used to demonstrate the sensitivity of  all these 
markers. The statistical analyses were done at 5% level of  
significance and p value < 0.05 was considered signifi-
cant. The statistical analysis was carried out using Statisti-
cal Package for SOcial Sciences (SPSS), Version 20.0
Results
Thirty eight histo-pathologically confirmed endometrial 
cancer patients were included first group. Forty weight 
matched cases of  abnormal uterine bleeding other than 
patients with endometrial cancer were included into 
group 2. 
The demographic characteristics such as age, height, 
weight and BMI were compared between two groups. 
There parameters did not differ significantly between 
study groups. Table 1. The hormonal imbalance in 
post-menopausal stage can contribute to the change in 
the tumour markers levels. Therefore, menopausal status 
also matched between two groups. Details are given in Ta-
ble 1. In study group 1, endometrioid adenocarcinoma In 
study group 1, endometrioid adenocarcinoma of  uterus 
accounted for 36 (95%) of  subjects on histopathological
analysis. One case each of  uterine papillary serous carci-
noma and poorly differentiated carcinoma were included 
in the study.
Among the tumor markers, serum levels of  CA15-3, CA 
125, CEA and prolactin were significantly high in patients 
with carcinoma than AUB patients (Table 2). than AUB 
patients Table 2.  We carried out correlation analysis be-
tween/ among the different parameters in study group 
consisting of  endometrial carcinoma cases. No signifi-
cant correlation was observed between CA 125, CA 15-3, 
CEA, and Prolactin.
Table 1: Comparison of demographic characteristics among patients with 
endometrial cancer and abnormal uterine bleeding 
 







Age (years) 49.8±7.2 48.3±4.5 NS 
Height (cm) 151.3±5.5 152.7±4.5 NS 
Weight (kg) 60.2±11.5 59.4±12.6 NS 
BMI (kg/m2) 26.4±5.7 25.4±5.1 NS 
Menopausal status* 
(Pre / Post) 
13 / 25 14 / 26 NS 
 
Data are expressed as Mean±SD, * indicates number of women in each  
group; NS- not significant 
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Table 2: Comparison of CA 15-3, CA 125, CEA, and prolactin among patients  





(n = 38) 
Abnormal 
uterine bleeding  
(n=40) 
p value 
CA 15-3 (U/mL) 21.97 (12.53 – 48.51) 
18.75 
 (9.38 – 23.89) 
0.048* 












                 
                            Data are expressed as median (IQR) IQR – Inter-quartile range; *-Statistically significant 
 
ROC curves were plotted for serum levels of  CA 125, CA 
15 -3, CEA and Prolactin to obtain optimal cut off  values 
to distinguish between endometrial cancer and abnormal 
uterine bleeding.  The ROC curve for CA 15-3 showed 
an area under curve AUC of  0.630. The sensitivity and 
specificity for the cut off  of  27.55 U/mL were 44.74% 
and 82.5% respectively. Positive predictive value PPV of  
70.8% and Negative predictive value NPV of  61.1 % 
were obtained with the same cut off.  
AUC of  0.660 was obtained in ROC curve for CA-125. 
A cut off  of  17.8U/mL showed a sensitivity and spec-
ificity of  52.63% and 80% respectively. PPV of  71.4% 
and NPV of  64% were obtained with the same cut off. 
The ROC curve for CEA showed an AUC of  0.628. The 
sensitivity and specificity for the cutoff  of  3.6µg/L were 
34.21% and 95% respectively. A PPV of  86.7% and NPV 
of  60.3% were obtained with the same cut off.  Area 
under curve of  0.634 was obtained for ROC curve for 
Prolactin. A cut off  of  11.27ng/mL showed a sensitivity 
and specificity of  38.64% and 87.5% respectively. PPV of  
73.68% and NPV of  59.3% were obtained with the same
cut off  value (Table 3).cut off  value Table 3. All tumor 
markers in our study had a very good specificity, but very 
less sensitivity at the cut off  when taken individually. 
Table 3: Sensitivity, specificity, PPV and NPV for tumor markers in endometrial cancer 
 
Parameter AUC Cut off value Sensitivity Specificity PPV NPV 
CA15-3 0.630 27.55U/mL 44.74% 82.50% 70.8% 61.1% 
CA125 0.660 17.8U/mL 52.63% 80.00% 71.4% 64% 
CEA 0.628 3.6µg/L 34.21% 95.00% 86.7% 60.3% 
Prolactin 0.634 11.27ng/mL 38.64% 87.5% 73.7% 59.3% 
 
AUC – area under curve for ROC, PPV – Positive predictive value, NPV – Negative predictive value 
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Discussion
Endometrial cancer is a challenging gynecological disease, 
where a noninvasive screening method is not available. 
In this study, we estimated serum concentrations of  CA 
125, CA 15-3, CEA and prolactin and their utility in diag-
nosis of  endometrial carcinoma. There are contradictory 
reports regarding CA 15-3 levels in endometrial carcino-
ma patients. Scambia et al and Panici et al have reported 
an increase in the levels of  CA 15-3 in carcinoma cases 
when compared with endometrial hyperplasia patients8,9. 
In our study, CA 15-3 levels are significantly increased 
in carcinoma patients in comparison with patients with 
uterine bleeding. Both these studies are limited by lack of  
control group. In contrast to these studies Kanat-Pektas 
et al observed low values of  CA 15-3 in patients with en-
dometrial cancer patients when compared to controls12.
The increase in CA 15-3 observed in our study might be 
because of  increased shedding of  cancer antigens to the 
blood stream. 
Erbagci et al studied the variation in levels of  CA-125, 
CA 19-9, CA 15-3, AFP and CEA with menstrual cycle
in small number of  healthy women. The blood samples 
were collected between 7th and 21st day of  menstrual 
cycle. The mid luteal phase concentrations of  CA 15-3 
were significantly higher than mid follicular phase values. 
There is no significant difference in the level of  other 
tumour markers including CA 125. In our study most of  
the women came to the hospital with the complaints of  
prolonged bleeding. Therefore phase of  menstrual cycle 
cannot be predicted since they have prolonged menstrual 
phase18. 
Even though several studies have reported the importance 
of  CA 125 in the diagnosis of  ovarian tumor, only limited 
studies have assessed its role in endometrial cancer. In 
our study the levels of  CA 125 are higher in endometri-
al cancer patients when compared with abnormal uterine 
bleeding patients. These findings are in accordance with 
previous studies and the elevation of  CA 125 is due to the 
increased synthesis of  this cancer antigen by endometrial 
tumor cells12,19,20. 
Jiang T et al studied importance of  preoperative CA 125 
levels, age menopausal status and tumor histology in a 
large number of  995 endometrial cancer patients. The 
study showed that CA 125 levels had significant asso-
ciation with age and menopausal status, but it was not 
associated with tumour histology. They have suggested 
different cut-off  values for  prediction of  lymph node 
metastasis and adnexal involvement and concluded that 
preoperative CA 125 levels has to be involved in the deci-
sion of  management21. 
CA 125 levels are elevated in benign physiological and 
pathological conditions including menstrual cycle, preg-
nancy, endometriosis and also in malignant conditions 
such as endometrial carcinoma22 . In order to differentiate 
those conditions from malignancy, patients with abnor-
mal uterine bleeding due to non-malignant cause were in-
cluded in this study for comparison. The median value of  
CA-125 is significantly higher 19.85 U/ml in patients with 
endometrial carcinoma than patients with AUB 10.95 U/
ml. This shows that CA-125 can differentiate malignan-
cy from non-malignant endometrial conditions, though 
all patients presented with similar symptoms. A study by 
Povolotskaya N et al revealed a preoperative CA 125 level 
greater than 28 U/ml had significantly correlation with 
patient’s age, tumour grade and unfavorable histological 
type in 98 uterine cancer patients. They concluded that 
CA 125 is an inexpensive and reproducible tumour mark-
er providing information about the metastasis and prog-
nosis in endometrial cancer23.
CEA is a non-specific tumor marker for gastrointestinal 
tract tumor and their alteration is not reported much in 
endometrial cancer. Previous study by Kanat-Pektas et al 
did not observe any difference in CEA levels between 
endometrial cancer patients and healthy controls12. In 
current study CEA levels are significantly higher in en-
dometrial cancer cases in comparison with women with 
abnormal uterine bleeding. CEA is well known marker 
of  colorectal cancer. However, elevated levels of  CEA 
are reported in many carcinomas of  epithelial origin like, 
lung adenocarcinoma, ovarian carcinoma and endometri-
al adenocarcinoma24. Kozakiewicz B et al showed that el-
evated CEA levels were not sensitive and specific enough 
to diagnose and monitor treatment of  endometrial can-
cer25 .
Prolactin has been proposed as one of  biomarkers in en-
dometrial cancer and previous investigators have docu-
mented an increase in prolactin levels in endometrial car-
cinoma cases11,12. We observed significantly high serum 
levels of  prolactin in cancer patients when compared to 
abnormal uterine bleeding group. The higher levels of  
prolactin may be explained by excessive prolactin release 
from the endometrial tumor cells12 .
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Diagnostic utility of  serum tumor markers in endo-
metrial carcinoma
The cut offs provided by ROC curve analysis were used 
to distinguish endometrial cancer patients and AUB 
cases. The cutoff  of  27.55 U/mL for CA 15-3 showed 
sensitivity, specificity, PPV and NPV of  44.74%, 82.5%, 
70.8% and 61.1% respectively. A cut off  of  17.8 U/mL 
for CA 125 showed sensitivity, specificity, PPV and NPV 
of  52.63%, 80%, 71.4% and 64%. Even though CEA 
and prolactin have high specificity, their low sensitivity 
prevents the use of  these two markers to differentiate 
EC and AUB. When AUC was compared for diagnos-
tic significance, CA125 had highest AUC of  0.66. 
Kurihara et al. suggested a CA 125 cut-off  of  20 U/ml 
for predicting myometrial infiltration with sensitivity of  
69.0%, specificity of  74.1%, positive predictive value of  
58.8% and negative predictive value of  81.6%. They have 
also found that elevated CA 125 levels is usually associ-
ated with advanced stage and poorer clinical outcome26. 
A study by Kanat-Pektas et al. showed similar diagnostic 
power for CA 125. The sensitivity, specificity, PPV and 
NPV for CA 125 in their study was 42.2%, 87.4%, 77% 
and 60.2% respectively12.  Among the tumour markers 
analysed, CA-125 has the comparatively better sensitivity, 
specificity and high AUC with the cut-off  of  17.8 U/mL. 
Therefore CA-125 can differentiate EC in AUB patients 
from uterine bleeding due to other causes. 
Limitations of  the study
i. The study included small number of  patients.
ii. Normal healthy controls were not included since the 
study was designed to differentiate or diagnose endome-
trial carcinoma in patients present with AUB and in fu-
ture study design healthy control group as well as patients 
with benign uterine diseases will be included. 
Conclusion
We found that serum concentrations of  CA 125, CA 15-3, 
CEA, and Prolactin were significantly higher in endome-
trial cancer. In addition, we observed that as an individual 
tumor marker, serum CA 125 has the best diagnostic util-
ity in differentiating endometrial cancer in patients pre-
senting with abnormal uterine bleeding. With reasonable 
sensitivity and specificity observed in the study, we pro-
pose that CA 125 can be best, single and economical test 
in diagnosing endometrial cancer. 
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